These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23532175)

  • 1. EGFR signalling and oncogenic pathway signature in colorectal cancer.
    Sahin IH; Oktay AA
    Gut; 2013 Nov; 62(11):1670. PubMed ID: 23532175
    [No Abstract]   [Full Text] [Related]  

  • 2. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
    Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
    Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 4. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].
    Ueno T; Moriwaki T; Hyodo I
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():477-81. PubMed ID: 22214007
    [No Abstract]   [Full Text] [Related]  

  • 6. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond KRAS: a new approach in metastatic colorectal cancer.
    Winder T; Lenz HJ
    Lancet Oncol; 2010 Aug; 11(8):706-7. PubMed ID: 20619738
    [No Abstract]   [Full Text] [Related]  

  • 8. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 9. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
    de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
    J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
    [No Abstract]   [Full Text] [Related]  

  • 11. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
    De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
    Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acta Oncologica and a new generation of scientists in oncology.
    Glimelius B; Johansen C; Muren LP; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):849-51. PubMed ID: 24954366
    [No Abstract]   [Full Text] [Related]  

  • 13. EGFR FISH in colorectal cancer: what is the current reality?
    Moroni M; Sartore-Bianchi A; Veronese S; Siena S
    Lancet Oncol; 2008 May; 9(5):402-3. PubMed ID: 18452847
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
    Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Brandi G; Biasco G; Tavolari S
    J Natl Cancer Inst; 2011 Aug; 103(16):1278. PubMed ID: 21775746
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 19. RAS mutations in colorectal cancer.
    Douillard JY; Rong A; Sidhu R
    N Engl J Med; 2013 Nov; 369(22):2159-60. PubMed ID: 24283232
    [No Abstract]   [Full Text] [Related]  

  • 20. RAS mutations in colorectal cancer.
    Sunakawa Y; Lenz HJ; Ichikawa W
    N Engl J Med; 2013 Nov; 369(22):2159. PubMed ID: 24283233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.